Rehabilitation Center, Central Clinical Hospital of the Ministry of the Interior and Administration, Warsaw, Poland.
Rheumatology and Internal Disease Department, Central Clinical Hospital of the Ministry of the Interior and Administration, Warsaw, Poland.
Curr Rheumatol Rev. 2022;18(3):212-223. doi: 10.2174/1573397118666220215092045.
The hand is an excellent work tool that provides the functional ability to mechanical work. The hand is affected in rheumatoid arthritis (RA) patients, it is a significant problem in the functional sphere as a result of deformities, the grasping function limitation and muscle strength.
The aim of the study was the assessment of grip strength, endurance and manipulation abilities of rheumatoid hands with or without deformities treated with methotrexate (MTX) or MTX plus biologics (MTX+BIO).
The study involved 80 RA women, (40 received MTX+BIO, 40 MTX), treated at the Rheumatology Department of the Central Clinical Hospital of Interior Affairs in Warsaw. VASpain, DAS28, SDAI, HAQ, HAQ hands, estimation of hand grip strength, endurance, and manipulation ability were analyzed.
In group MTX+BIO, values of DAS28 (3.7±1.3 vs. 4.3±1.2, p=0.019), HAQ (0.72 ± 0.57 vs. 1.08± 0.87, p=0.011) and HAQ-hand (0.85±0.65 vs. 1.19±0.68, p=0.024) were statistically lower than in MTX group. Hand deformations were recorded in 35 (43.7%) cases, 16 (40%) in MTX group, 19 (47.5%) in MTX+BIO. Comparison of grip strength, endurance, and manipulation ability showed better results in MTX+BIO group with deformities (significance level from 0.013 to 0.046) than in MTX group. Relative differences in hand function in MTX + BIO group ranged from 10.8% (maximal power grip strength) to 127.6% (minimal hand endurance), after disease duration adjustment - from 28.2% (maximal power grip strength) to 148.4% (minimal hand endurance).
Measuring grip strength, hand endurance, manipulation abilities are useful in RA patients with hand deformities.
手是一种出色的工作工具，它提供了进行机械工作的功能能力。在类风湿关节炎（RA）患者中，手会受到影响，这是由于畸形、抓握功能受限和肌肉力量导致的功能领域中的一个重大问题。
本研究旨在评估接受甲氨蝶呤（MTX）或 MTX 联合生物制剂（MTX+BIO）治疗的有或无畸形的 RA 手部的握力、耐力和操作能力。
该研究纳入了 80 名 RA 女性患者（40 名接受 MTX+BIO，40 名接受 MTX），她们在华沙内政中央临床医院的风湿病科接受治疗。分析了 VASpain、DAS28、SDAI、HAQ、HAQ 手部、手部握力、耐力和操作能力的评估结果。
在 MTX+BIO 组中，DAS28（3.7±1.3 对 4.3±1.2，p=0.019）、HAQ（0.72 ± 0.57 对 1.08±0.87，p=0.011）和 HAQ 手部（0.85±0.65 对 1.19±0.68，p=0.024）的值均低于 MTX 组。35 例（43.7%）患者存在手部畸形，MTX 组 16 例（40%），MTX+BIO 组 19 例（47.5%）。与 MTX 组相比，畸形组 MTX+BIO 组的握力、耐力和操作能力更好（显著性水平从 0.013 到 0.046）。MTX+BIO 组手部功能的相对差异范围为 10.8%（最大力量握力）至 127.6%（最小手部耐力），在疾病持续时间调整后为 28.2%（最大力量握力）至 148.4%（最小手部耐力）。
在手部畸形的 RA 患者中，测量握力、手部耐力和操作能力是有用的。
